Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Strata Skin Sciences (SSKN) has provided an update.
STRATA Skin Sciences, Inc. revealed preliminary financial figures for Q2 2024, with revenues expected between $8.0 million to $8.4 million, despite a slight decrease in its XTRAC® device installations. In contrast, installations of TheraClear®X devices showed growth, and the company ended the quarter with $6.8 million in cash and equivalents. The report also contains forward-looking statements, advising investors of potential risks and urging them to review further disclosures for a more informed perspective.
For an in-depth examination of SSKN stock, go to TipRanks’ Stock Analysis page.
